HeartBeam Launches Pilot Study for On-Demand 12-Lead ECG Patch Aimed at Ischemia Detection
HeartBeam Inc. has initiated a pilot study for its investigational on-demand 12-lead ECG patch in coronary artery disease patients, potentially expanding ambulatory cardiac monitoring into ischemia detection within a $2 billion market.
HeartBeam Inc. (NASDAQ: BEAT) announced the start of a pilot study evaluating its investigational on-demand 12-lead ECG patch in approximately 50 patients with suspected coronary artery disease. The study, taking place at two hospitals in Belgrade, Serbia, aims to compare synthesized 12-lead ECG readings from the patch against standard 12-lead ECGs immediately after exercise stress testing. This research supports HeartBeam’s regulatory strategy for a device designed to expand ambulatory cardiac monitoring beyond rhythm assessment into ischemia detection, targeting the established approximately $2 billion patch-based monitoring market.
The significance of this study lies in its potential to address a critical gap in cardiac care. Current ambulatory ECG patches primarily focus on detecting arrhythmias, but they do not effectively identify ischemia—a condition where blood flow to the heart is reduced, often indicating coronary artery disease. By enabling ischemia detection outside of clinical settings, HeartBeam’s technology could allow for earlier intervention and better management of heart disease, which remains a leading cause of death globally.
HeartBeam’s platform technology is the first cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a 12-lead ECG. The company has already received FDA clearance for arrhythmia assessment in December 2024 and for its 12-lead ECG synthesis software in December 2025. With over 20 issued patents related to its technology, HeartBeam is positioning itself to redefine cardiac health management by providing actionable heart intelligence to physicians, allowing them to identify trends and acute conditions and direct patients to appropriate care outside of medical facilities.
According to the company, the pilot study is a key step toward expanding the indications for use of its technology. The full press release detailing the study is available at https://ibn.fm/x7016. For more information about HeartBeam and its cleared indications for use, visit https://www.heartbeam.com/indications.
The implications of this study are broad. If successful, HeartBeam’s patch could become a tool for routine monitoring of high-risk patients, potentially reducing hospital visits and enabling more proactive care. The company’s technology could also lower healthcare costs by catching ischemic events earlier and preventing complications. As the patch-based monitoring market continues to grow, HeartBeam’s entry into ischemia detection could capture a significant share, offering a competitive advantage over existing solutions.
Investors and industry watchers are closely monitoring HeartBeam’s progress. The latest news and updates are available in the company’s newsroom at https://ibn.fm/BEAT.